Gemcitabine 100mg/ml concentrate for solution for infusion concentrate for solution for i/v infusion

Quốc gia: Armenia

Ngôn ngữ: Tiếng Anh

Nguồn: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Thành phần hoạt chất:

gemcitabine (gemcitabine hydrochloride)

Sẵn có từ:

Accord Healthcare Limited

Mã ATC:

L01BC05

INN (Tên quốc tế):

gemcitabine (gemcitabine hydrochloride)

Liều dùng:

100mg/ml

Dạng dược phẩm:

concentrate for solution for i/v infusion

Các đơn vị trong gói:

glass vial 10ml

Loại thuốc theo toa:

Prescription

Tình trạng ủy quyền:

Registered

Ngày ủy quyền:

2021-05-21

Tờ rơi thông tin

PACKAGE LEAFLET: INFORMATION FOR THE USER
GEMCITABINE 100 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
GEMCITABINE
Read all of this leaflet carefully before you start using this
medicine

Keep this leaflet. You may need to read it again.

If you have further questions, please ask your doctor, nurse or
pharmacist.

This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if their symptoms are the
same as yours.

If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet, please tell your doctor,
nurse or pharmacist.
IN THIS LEAFLET:
1. What Gemcitabine Concentrate for solution for infusion is and what
it is used for
2. Before you are given Gemcitabine Concentrate for solution for
infusion
3. How Gemcitabine Concentrate for solution for infusion is given
4. Possible side effects
5. How to store Gemcitabine Concentrate for solution for infusion
6. Further information
1. WHAT GEMCITABINE CONCENTRATE FOR SOLUTION FOR INFUSION
IS AND WHAT IT IS USED FOR
The name of your medicine is ‘
GEMCITABINE 100 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
’ but in the rest of the leaflet
it will be called ‘Gemcitabine concentrate for solution for
infusion’.
Gemcitabine Concentrate for solution for infusion belongs to a group
of medicines called “cytotoxics”. These medicines kill
dividing cells, including cancer cells.
Gemcitabine Concentrate for solution for infusion may be given alone
or in combination with other anti-cancer medicines,
depending on the type of cancer.
Gemcitabine Concentrate for solution for infusion is used in the
treatment of the following types of cancer:

non-small cell lung cancer (NSCLC), alone or together with cisplatin.

pancreatic cancer.

breast cancer, together with paclitaxel.

ovarian cancer, together with carboplatin.

bladder cancer, together with cisplatin.
2. BEFORE YOU ARE GIVEN GEMCITABINE CONCENTRATE FOR SOLUTION FOR
INFUSION
YOU SHOULD NOT BE GIVEN GEMCITABINE CONCENTRATE FOR

Đặc tính sản phẩm

12/20/2020
Gemcitabine 100 mg/ml Concentrate for Solution for Infusion - Summary
of Product Characteristics (SmPC) - print friendly - (emc)
https://www.medicines.org.uk/emc/product/2839/smpc/print
1/15
GEMCITABINE 100 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
Summary of Product Characteristics Updated 18-Mar-2019 | Accord
Healthcare Limited
1. NAME OF THE MEDICINAL PRODUCT
Gemcitabine100 mg/ml Concentrate for Solution for Infusion
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains Gemcitabine hydrochloride equivalent to 100 mg
gemcitabine.
Each vial of 2 ml concentrate for solution for infusion contains
Gemcitabine hydrochloride equivalent to 200 mg
gemcitabine.
Each vial of 10 ml concentrate for solution for infusion contains
Gemcitabine hydrochloride equivalent to 1000 mg
gemcitabine
Each vial of 15 ml concentrate for solution for infusion contains
Gemcitabine hydrochloride equivalent to 1500 mg
gemcitabine
Each vial of 20 ml concentrate for solution for infusion contains
Gemcitabine hydrochloride equivalent to 2000 mg
gemcitabine
EXCIPIENTS:
8.87 mg/ml (0.39 mmol/ml) sodium.
440 mg/ml ethanol anhydrous
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Concentrate for solution for infusion
Clear, colourless to slightly yellow solution
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Gemcitabine is indicated for the treatment of locally advanced or
metastatic bladder cancer in combination with cisplatin.
Gemcitabine is indicated for treatment of patients with locally
advanced or metastatic adenocarcinoma of the pancreas.
Gemcitabine, in combination with cisplatin, is indicated as first-line
treatment of patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy
can be considered in elderly patients or those
with performance status 2.
Gemcitabine is indicated for the treatment of patients with locally
advanced or metastatic epithelial ovarian carcinoma, in
combination with carboplatin, in patients with relapsed disease
following a r